Building the Future of Pharmaceutical Manufacturing: A Phased Approach to Dark Factories
Life sciences organizations are navigating a perfect storm: surging global patient demand, compressed drug development lifecycles and relentless margin compression in a highly price-sensitive market....
Read MoreReimagining Pharmaceutical Manufacturing: Why the latest E2500-25 Standard Revision Demands Immediate Action
Speed to patient is a primary driver behind the industry’s shift toward modern commissioning and qualification (C&Q) practices while still ensuring product quality and patient...
Read MoreOptimizing Asset Performance: A Risk-Based Approach to Calibration Management
How does your engineering organization determine its instrument calibration test points, tolerance limits and cycle frequencies? For decades, industrial maintenance has relied on an arbitrary...
Read MoreBuilding the Future of Life Sciences—Together
When people think about advancing the life sciences industry, they often picture groundbreaking therapies, cutting-edge manufacturing technologies, or state-of-the-art facilities. But none of those innovations...
Read MoreAccelerating Capex Efficiency and Operational Readiness with Digital Twins
Bringing a new life sciences facility online is no longer just a construction milestone — it is a knowledge milestone. Most project delays do not come...
Read MoreMy Journey with CAI
Written by Joe Robinson, Client Manager My History with CAI I started my career with CAI in 2005 after a successful 20-year Military career. After...
Read MoreCAI Closes Recapitalization with JLL Partners, Unlocking New Opportunities for Growth
New partnership positions CAI to accelerate its global expansion, technology investment and enhanced service offerings INDIANAPOLIS, July 1, 2026 – CAI, a professional services firm...
Read MoreReducing OPEX and Strengthening Operational Readiness with Digital Twins
After startup, facilities drift into uncertainty as processes evolve and equipment ages. Digital twins restore visibility, reduce operational expenditure, and strengthen readiness by modeling, monitoring,...
Read MoreStewardship Over Automation: FDA Redefines AI Accountability in Pharma
In response to a landmark FDA warning, this analysis explores how regulators are shifting from automation to accountable stewardship, redefining governance expectations for AI across...
Read More
